ArriVent BioPharma, Inc. announced initial Phase 1 results for ARR-217 (MRG007), a cadherin-17-targeting antibody-drug conjugate developed in partnership with Lepu Biopharma Co., Ltd. The data, ...
Total revenue increased 7% to a record $11.0M from $10.2M in the same prior year period. During 2026, the Company has reduced ...
ArriVent BioPharma (NASDAQ:AVBP) delivered early oncology updates with initial Phase 1 results for ARR-217, an investigational antibody-drug conjugate targeting cadherin-17 (CDH17). The candidate, ...
AI selloff nears a bottom as SMH rotates into financials and software. Click for a look at the tech sector and its key ...
Michael Saylor's Strategy pauses Bitcoin purchases and repurchases $205 million in STRC preferred stock, with MSTR stock ...
Novartis' oral BTK inhibitor remibrutinib (Rhapsido) met its primary endpoint in Phase III REMODEL-1 and REMODEL-2 relapsing ...
Are you feeling anxious about the intense price fluctuations in AI and semiconductor-related stocks?With some stocks falling ...
Apax, Clearlake, EQT, Francisco Partners, Hg, Permira, Thoma Bravo and Vista spoke with PEI Private Equity about defensible ...
Gagan Sharma appointed as President, Specialty Business at Evonile Pharma Limited. Designated as Senior Management Personnel ...
Responses were deep and durable, with 65% ongoing at clinical cutoff; Results support continued evaluation of the ...
VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of user-centric security solutions for a safer connected world, announces its third-quarter revenue for fiscal year 2026 (July 1 to ...
ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results